

# Alert card

Important safety information

Lojuxta<sup>®</sup> ▼ capsules  
(lomitapide)

▼ Call for reporting

Report any adverse drug reactions :

1. PharmaKnowl Consulting

Tel: +966112777729 - Tel: +966112404409 - Email: QPPV-Saudi@pharmaknowl.com

2. The National Pharmacovigilance Centre (NPC) Saudi Food and Drug Authority (SFDA):

SFDA call center: 19999 / E-mail: npc.drug@sfd.gov.sa / Website: <http://ade.sfd.gov.sa/>

Please see section 4.5 of the Summary of Product Characteristics for the list of interactions with other medicines before giving the person named on this card any further medications. If you have any questions or need a replacement card, please contact:

Amryt Pharmaceuticals Information on +966112777729 or e-mail [medinfo@amrytpharma.com](mailto:medinfo@amrytpharma.com), [QPPV-Saudi@pharmaknowl.com](mailto:QPPV-Saudi@pharmaknowl.com)

**Patient's name:** .....

**Doctor's name:** .....

**Doctor's phone number:** .....

**Date Lojuxta treatment started:** .....

Date of preparation: Feb 2021

# Information for the doctor or pharmacist

This patient has been prescribed Lojuxta.

Lojuxta could interact with the following drugs:

- CYP 3A4 inhibitors
- CYP 3A4 inducers
- Coumarin anticoagulants
- Statins
- P-gp substrates
- Oestrogen-containing oral contraceptives

# Important safety information



**Please keep this card with you at all times.**

**Show this card to any doctor or pharmacist involved in your treatment.**

**Please make sure that you have a list of all your other medicines with you, including herbal and non prescription medicines, when you visit your doctor or pharmacist.**

This document is approved by The Executive Directorate of Pharmacovigilance, at SFDA. For more copies of this, contact Amryt Pharmaceuticals Information on +966 112 777 729, e-mail [medinfo@amrytpharma.com](mailto:medinfo@amrytpharma.com), [QPPV-Saudi@pharmaknowl.com](mailto:QPPV-Saudi@pharmaknowl.com)